Alethio Therapeutics
An Oxford University spinout developing therapies for chronic blood cancers, starting with the antibody ATX-011.
Europe's most interesting startup stories. Every week.
No spam. Unsubscribe anytime.
Podcast Episode
🎙️ Deep Dive
Alethio, Candi Solar, Vensum Power — $90M for therapies, $50M for solar and €9M for power efficiency — Daily News November 6, 2026
Listen to the episodeAbout Alethio Therapeutics
Alethio Therapeutics was founded in 2021 as Alethiomics, a University of Oxford spinout created by physician-scientists Adam Mead and Beth Psaila, and is based at Abingdon Science Park near Oxford. In December 2021 it raised a £6 million seed round led by Oxford Science Enterprises, with Cancer Research UK as a minority shareholder; in October 2025 it changed its name and appointed Rohit Batta as CEO. It develops therapies for myeloproliferative neoplasms (MPNs), chronic blood cancers, using its ARTEMIS discovery platform. Lead programme ATX-011 is a monoclonal antibody targeting the G6B receptor to normalise platelet counts in essential thrombocythaemia: it is still preclinical, with IND-enabling studies under way. On 5 November 2026 it announced an oversubscribed $90 million (£67 million) Series A co-led by Sofinnova Partners and RA Capital, which will fund a Phase 1/2a study of ATX-011 and move other programmes towards IND.
The Story
University of Oxford spinout founded in 2021 as Alethiomics by Adam Mead and Beth Psaila; renamed Alethio Therapeutics in October 2025.
How Alethio Therapeutics works
Business Model
Clinical development of proprietary drugs, with potential licensing or partnership deals.
Products & Services
Key Products
- ATX-011
- ARTEMIS discovery platform
Core Use Cases
- Treatment of essential thrombocythaemia
- Therapies for myeloproliferative neoplasms
Market & Clients
Key Customers
Healthcare systems, haematologists and pharmaceutical partners.
Geographic Presence
How Alethio Therapeutics competes
Competitive Advantages
- Oxford academic origin
- First-in-class G6B target
- MPN-focused pipeline
How Alethio Therapeutics grows
Growth Strategy
Start the ATX-011 Phase 1/2a in essential thrombocythaemia and move further programmes towards IND.
Distribution Model
Direct clinical development and possible pharmaceutical partnerships.
Regulatory Context
Clinical trial authorisations (IND/CTA) and medicine approvals.
Key Risks
- Clinical failure
- Adverse events
- Regulatory timelines
- Dependence on further capital
Strategic Insights
- The round funds the move from preclinical biotech to clinical-stage company.
- Value will depend on safety and activity data from first-in-human studies.
Funding & Investors
Funding Rounds
- 2026 - Series A: $90M (£67M)
Lead: Sofinnova Partners, RA Capital Management - 2021 - Seed: £6M
Lead: Oxford Science Enterprises
Key Investors
Founding Team
Founders
Key Executives
- Rohit Batta - CEO
Key Metrics
Lessons from Alethio Therapeutics
- In biotech, a large round does not replace clinical validation.
Similar Startups
Ternary Therapeutics
London biotech founded in 2024 designing molecular glues with AI. In March 2026 it announced a €4.1 million seed.
Read AnalysisOxford Medical Simulation
UK clinical-simulation company using VR and AI, founded in 2017. On 16 March 2026 it announced £5 million of growth financing from Salica.
Read AnalysisBioniq
London company founded in 2019 offering supplement formulas personalised from a customer assessment. In 2026 Herbalife acquired its core assets.
Read AnalysisSources
- Alethio Therapeutics Raises $90 Million (£67 Million) in Oversubscribed Series A Financing — Alethio Therapeutics / GlobeNewswire
- Alethio Therapeutics launches with new CEO and Chair — Cancer Research Horizons
- Alethiomics launch and £6m financing — Alethiomics
- Oxford spin-out Alethio Therapeutics raises €80.46 million Series A to advance targeted blood cancer therapies — EU-Startups
- Alethio Raises $90 Million to Advance First-in-Class G6B Antibody for Essential Thrombocythemia — BioPharm International